【摘要】 目的观察FOLFOX4方案治疗晚期胃癌的近期疗效和毒副反应。方法42例晚期胃癌患者接受FOLFOX4方案化疗,奥沙利铂85mg/m2,静脉滴注2h,d1;醛氢叶酸200mg/m2,静脉滴注2h,d1、d2;氟尿嘧啶400mg/m2,快速静脉滴注,d1、d2,600mg/m2,持续静脉滴注22h,d1、d2。每2周重复。4个周期后以WHO实体瘤疗效评定标准评价疗效及毒副反应。结果全组42例均可评价疗效,其中完全缓解(CR)1例,部分缓解(PR)19例,稳定(SD)14例,进展(PD)8例,总有效率(CR+PR)47.6%。中位肿瘤进展时间(TTP)为6个月,中位生存时间(MST)为9.5个月。毒副反应主要是骨髓抑制,白细胞降低发生率达80.9%,其次为胃肠道反应,恶心呕吐发生率78.6%,口腔黏膜炎19.0%,腹泻21.4%,无Ⅲ/Ⅳ度胃肠道反应;周围神经毒性发生率为66.7%。结论FOLFOX4方案治疗晚期胃癌的近期疗效较好,毒副反应可以耐受。更多还原

【Abstract】 Objective To evaluate the efficacy and adverse effects of oxaliplatin(OXA) combined with 5-fluorouracil(5-Fu) and calcium folinate(LV) in the treatment of patients with advanced gastric cancer.Methods Forty-two patients with advanced gastric cancer were treated with FOLFOX4 regimen:OXA 85mg/m2 iv 2 h,d1;LV 200 mg/m2 iv 2 h,d1 and d2,followed by 5-Fu 400 mg/m2 iv bolus and 5-Fu 600 mg/m2iv 22 h,d1 and d2.The regimen was repeated every 2 weeks.Efficacy and side effects were evaluated after 4 cycles.Results All patients could be evaluated for therapeutic efficacy.One patient achieved compete response(CR),19 patients partial response(PR),14 patients stable disease(SD) and eight patients progression disease(PD),Overall response rate was 47.6%.Median time to progress(TTP) was six months,MST was 9.5 months.The major toxic reactions included nausea,vomiting,leucopenia and peripheral nerve toxicity.Conclusion This study shows that the regimen of FOLFOX 4 is effective and tolerable in advanced gastric cancer.更多还原